This company has been marked as potentially delisted and may not be actively trading. NASDAQ:JUNS Jupiter Neurosciences (JUNS) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsCompetitorsEarningsFDA EventsHeadlinesInsider TradesTrendsBuy This Stock About Jupiter Neurosciences Stock (NASDAQ:JUNS) 30 days 90 days 365 days Advanced Chart Get Jupiter Neurosciences alerts:Sign Up Key Stats Today's Range$1.24▼$1.4050-Day Range N/A52-Week Range N/AVolume75,478 shsAverage Volume175,396 shsMarket Capitalization$43.19 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingStrong Buy Company Overview Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease. In addition, it is developing JNS109 for amyotrophic lateral sclerosis; JNS110 for traumatic brain injury/concussion; and JNS120 for covid-19 treatment. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. The company was founded in 2016 and is headquartered in Jupiter, Florida. Read More Receive JUNS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Jupiter Neurosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. JUNS Stock News HeadlinesJupiter Neurosciences announces launch of Nugevia websiteAugust 26, 2025 | msn.comJupiter Neurosciences Launches Nugevia™ Website and Opens Pre-Orders for Groundbreaking Longevity SupplementsAugust 26, 2025 | markets.businessinsider.comFree: The Crypto Summit That Could Change Your Life27 industry leaders share urgent market intel (free access)... For a very limited time, you can claim your spot for FREE.September 4 at 2:00 AM | Crypto 101 Media (Ad)Longevity In A Capsule: Jupiter Neurosciences Launches First Three Supplements Under Nugevia(TM) BrandAugust 20, 2025 | theglobeandmail.comJupiter Neurosciences names Chris Webber as second Nugevia brand ambassadorAugust 19, 2025 | msn.comJupiter Neurosciences Names NBA Legend Chris Webber as Second Nugevia™ Brand AmbassadorAugust 19, 2025 | globenewswire.comJupiter Neurosciences Introduces Nugevia™ MND: A Cognitive Health Supplement Leveraging Clinically Validated NeuroscienceAugust 11, 2025 | finance.yahoo.comJupiter Neurosciences Highlights Critical Advancement of JOTROL™ Over Traditional Resveratrol with Breakthrough Bioavailability and CNS-Targeted ScienceJuly 23, 2025 | globenewswire.comSee More Headlines JUNS Stock Analysis - Frequently Asked Questions How were Jupiter Neurosciences' earnings last quarter? Jupiter Neurosciences, Inc. (NASDAQ:JUNS) posted its quarterly earnings results on Monday, August, 18th. The company reported ($0.07) EPS for the quarter, hitting analysts' consensus estimates of ($0.07). When did Jupiter Neurosciences IPO? Jupiter Neurosciences (JUNS) raised $11 million in an IPO on Tuesday, December 3rd 2024. The company issued 2,800,000 shares at $4.00 per share. Dominari Securities and Revere Securities served as the underwriters for the IPO. Company Calendar Last Earnings8/18/2025Today9/04/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryN/A Current SymbolNASDAQ:JUNS CIK1679628 Webwww.jupiterorphan.com Phone561 406 6154FaxN/AEmployees5Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$2.44 million Net MarginsN/A Pretax MarginN/A Return on Equity-835.24% Return on Assets-155.10% Debt Debt-to-Equity RatioN/A Current Ratio1.07 Quick Ratio1.07 Sales & Book Value Annual Sales$230 thousand Price / Sales187.78 Cash FlowN/A Price / Cash FlowN/A Book Value$0.04 per share Price / Book31.00Miscellaneous Outstanding Shares34,830,000Free FloatN/AMarket Cap$43.19 million OptionableNot Optionable BetaN/A 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:JUNS) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredFree: The Crypto Summit That Could Change Your Life27 industry leaders share urgent market intel (free access)... For a very limited time, you can claim your ...Crypto 101 Media | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…A new set of 7 AI stocks are DOMINATING the market. Here’s why one financial guru says they could be the mo...The Oxford Club | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jupiter Neurosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Jupiter Neurosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
